ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
- S&P, Nasdaq futures rise as JPMorgan, Goldman set to kick off earnings season
- Coinbase (COIN) direct listing IPO reference price set at $250
- Wells Fargo (WFC) Tops Q1 EPS by 35c
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to discuss these results and to answer questions.
To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 8283128. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).
ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
Lee Roth, Burns McClellan
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan (JPM) Tops Q1 EPS by $1.40, Revenues Beat
- Almost Two-Thirds of Home Offers Written By Redfin Agents Faced Bidding Wars in March
- Rarebreed Veterinary Partners Appoints Dr. Christina Tran and Dr. Amy Wallis to Its Board of Directors